mipasetamab uzoptirine

Mipasetamab uzoptirine is an antibody-drug conjugate (ADC) designed for the treatment of cancers, particularly solid tumors. It consists of a humanized IgG1 monoclonal antibody (mipasetamab) that specifically targets the AXL receptor tyrosine kinase, which is overexpressed in many solid tumors. The antibody is site-specifically conjugated via a valine-alanine cleavable linker to uzoptitine (PL1601), which contains SG3199, a highly potent pyrrolobenzodiazepine (PBD) dimer cytotoxin. Upon binding to AXL-expressing tumor cells, the ADC is internalized and releases SG3199 inside the cell after linker cleavage, leading to DNA cross-linking and subsequent cell death. Mipasetamab uzoptirine has been developed by ADC Therapeutics and Overland ADCT BioPharma for use as monotherapy or in combination with other agents such as gemcitabine in advanced solid tumors including sarcoma, pancreatic cancer, and non-small cell lung cancer[1][4][5][6][8].

Other names

mipasetamab uzoptirine